Evidence map›Paper›PMID 37961720›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Proteomic Network Analysis of Alzheimer's Disease Cerebrospinal Fluid Reveals Alterations Associated with

Eric B Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M Duong, Ekaterina S Gerasimov, Suda Parimala Ravindran, Valborg Gudmundsdottir, Elisabet A Frick, Gabriela T Gomez, Keenan A Walker and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Eric B DammerGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-2947-7606
Anantharaman ShantaramanGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Lingyan PingGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Duc M DuongGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Ekaterina S GerasimovDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Suda Parimala RavindranDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Valborg GudmundsdottirIcelandic Heart Association, Kopavogur, Iceland.
Elisabet A FrickIcelandic Heart Association, Kopavogur, Iceland.
Gabriela T GomezDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Keenan A WalkerLaboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.
Valur EmilssonIcelandic Heart Association, Kopavogur, Iceland.
Lori L JenningsNovartis Biomedical Research, Cambridge, MA, USA.
Vilmundur GudnasonIcelandic Heart Association, Kopavogur, Iceland.
Daniel WesternDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
James J LahGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Thomas S WingoGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Aliza P WingoGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Nicholas T SeyfriedGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Allan I LeveyGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Erik C B JohnsonGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-0604-2944
Emory University · USUniversity of Iceland · ISWashington University in St. Louis · USIcelandic Heart Association · ISJohns Hopkins University · USNational Institute on Aging · USNovartis (United States) · US

Funding

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Monica Willis Parker · 2020 to 2026
$29.0M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
The brain multi-omic approach to identify key molecular drivers of neuropsychiatric symptoms in Alzheimer's dementiaR01AG072120 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aliza Pham Wingo, Thomas Spurgeon Wingo · 2022 to 2026
$4.3M
Integrative genomic, transcriptomic, and proteomic analyses to investigate sex-specific differences in Alzheimer's DiseaseR01AG075827 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aliza Pham Wingo, Thomas Spurgeon Wingo · 2022 to 2026
$3.7M
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik studyR01AG065596 · NIA · ICELANDIC HEART ASSOCIATION · PI Valborg Gudmundsdottir · 2021 to 2026
$2.6M
Brain Proteomic Network Analysis to Elucidate Mechanisms and Biomarkers for Alzheimer's DiseaseK08AG068604 · NIA · EMORY UNIVERSITY · PI JOHNSON, ERIK C.B. · 2020 to 2024
$762k
AGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–
NIA NIH HHS K08 AG068604NIA NIH HHS N01 AG012100NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG065596NIA NIH HHS R01 AG070937NIA NIH HHS R01 AG072120NIA NIH HHS R01 AG075827NIA NIH HHS U01 AG061357
6 · The paper itself

Abstract

Alzheimer's disease (AD) is currently defined at the research level by the aggregation of amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure Aβ and tau pathology, few biomarkers are available to measure the complex pathophysiology that is associated with these two cardinal neuropathologies. Here we describe the proteomic landscape of cerebrospinal fluid (CSF) changes associated with Aβ and tau pathology in 300 individuals as assessed by two different proteomic technologies-tandem mass tag (TMT) mass spectrometry and SomaScan. Harmonization and integration of both data types allowed for generation of a robust protein co-expression network consisting of 34 modules derived from 5242 protein measurements, including disease-relevant modules associated with autophagy, ubiquitination, endocytosis, and glycolysis. Three modules strongly associated with the apolipoprotein E ε4 (

Identifiers

PMID37961720
PMCPMC10635242
OpenAlexW4388098929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.